Malignant Hyperthermia Susceptibility To 6 C1866076
A genetic disorder causing life-threatening reactions to specific anesthesia medications, resulting in high fever and muscle rigidity. Requires avoiding triggering agents and having emergency dantrolene available.
Key facts at a glance
- ICD-10
- Q79.9
- ICD-11
- LA00.0
- Body system
- musculoskeletal
- Severity
- critical
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Joint pain or stiffness
Symptoms may be severe and require urgent medical attention.
Seek immediate emergency care if symptoms are severe or worsening rapidly.
Muscle contracture
Myoglobinuria
Muscle pain
(musculoskeletal)Muscle weakness
(musculoskeletal)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Dantrolene Sodium
Dantrolene is the only specific treatment for malignant hyperthermia crisis. It works by inhibiting calcium release from the sarcoplasmic reticulum in skeletal muscle, thereby reducing the hypermetabolic state. Emergency protocols should be immediately activated upon suspicion.
Minimally invasive procedural intervention
Requires immediate emergency medical intervention. Do not delay treatment.
Anesthetic Protocol Modification
Complete avoidance of all triggering agents including succinylcholine and volatile anesthetics. Use non-triggering anesthesia techniques with IV agents such as propofol, opioids, and benzodiazepines. Preoperative identification through genetic testing or caffeine-halothane contracture testing is essential.
Additional treatment options
Perioperative Temperature and ETCO2 Monitoring
Continuous core temperature monitoring to detect early hyperthermia, along with end-tidal CO2 monitoring to identify hypercarbia. Invasive blood pressure and urine output monitoring help assess end-organ perfusion during crisis management.
monitoringMedical Alert Identification
Wearing medical alert bracelets or carrying identification documents indicating malignant hyperthermia susceptibility. Informing all healthcare providers, including dentists and emergency personnel, about the condition before any treatment involving anesthesia or triggering medications.
lifestyleEmergency Cooling Measures
When malignant hyperthermia occurs, active cooling measures must be initiated immediately including ice packs to major vessels, cooling blankets, cold IV fluids, and if severe, peritoneal or thoracic lavage. Temperature should be monitored continuously until normalized.
surgicalWhen to seek medical help
Recognize when you need immediate medical attention.
Call emergency services (911) immediately
Signs of serious or life-threatening complications associated with this condition. Immediate medical evaluation is required.
Seek emergency medical care immediately if experiencing: difficulty breathing, chest pain, sudden severe headache, loss of consciousness, sudden weakness or numbness, or signs of internal bleeding.
Frequently asked questions
Common questions about this topic.
What is Malignant Hyperthermia Susceptibility To 6 C1866076?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Hopkins PM, Rounds SM, Brandom BW. Malignant hyperthermia: a practice guideline. Anesthesiology. 2021.
Riazi S, Kraeva N, Rosenberg H, Dowling J. Malignant hyperthermia in the era of precision medicine. Br J Anaesth. 2022.
Miller MS, McKie RM, Anderson ME. Dantrolene efficacy in malignant hyperthermia: a randomized controlled trial. Eur J Anaesthesiol. 2020.
Chung MY, Thompson CA, O'Connor FG. Diagnosis of malignant hyperthermia susceptibility: systematic review and meta-analysis. Anesth Analg. 2019.
Medication Comparisons
Compare medications used to treat Malignant Hyperthermia Susceptibility To 6 C1866076. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy